Patents by Inventor Alan M. Krensky
Alan M. Krensky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9855330Abstract: Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a tumor antigen or an autoimmune antigen. In another embodiment, the method includes contacting the monocyte with an additional agent that enhances maturation of dendritic cells or induces immunological tolerance. The methods are of use in vivo, in vitro and ex vivo. In another aspect, the disclosure relates to compositions and methods for the treatment of tumors.Type: GrantFiled: June 6, 2016Date of Patent: January 2, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Alan M. Krensky, Carol Clayberger
-
Publication number: 20160346385Abstract: Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a tumor antigen or an autoimmune antigen. In another embodiment, the method includes contacting the monocyte with an additional agent that enhances maturation of dendritic cells or induces immunological tolerance. The methods are of use in vivo, in vitro and ex vivo. In another aspect, the disclosure relates to compositions and methods for the treatment of tumors.Type: ApplicationFiled: June 6, 2016Publication date: December 1, 2016Inventors: Alan M. Krensky, Carol Clayberger
-
Patent number: 9358285Abstract: Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a tumor antigen or an autoimmune antigen. In another embodiment, the method includes contacting the monocyte with an additional agent that enhances maturation of dendritic cells or induces immunological tolerance. The methods are of use in vivo, in vitro and ex vivo. In another aspect, the disclosure relates to compositions and methods for the treatment of tumors.Type: GrantFiled: July 25, 2014Date of Patent: June 7, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Alan M. Krensky, Carol Clayberger
-
Publication number: 20150023910Abstract: Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a tumor antigen or an autoimmune antigen. In another embodiment, the method includes contacting the monocyte with an additional agent that enhances maturation of dendritic cells or induces immunological tolerance. The methods are of use in vivo, in vitro and ex vivo. In another aspect, the disclosure relates to compositions and methods for the treatment of tumors.Type: ApplicationFiled: July 25, 2014Publication date: January 22, 2015Inventors: Alan M. Krensky, Carol Clayberger
-
Patent number: 8815229Abstract: Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a tumor antigen or an autoimmune antigen. In another embodiment, the method includes contacting the monocyte with an additional agent that enhances maturation of dendritic cells or induces immunological tolerance. The methods are of use in vivo, in vitro and ex vivo. In another aspect, the disclosure relates to compositions and methods for the treatment of tumors.Type: GrantFiled: October 8, 2010Date of Patent: August 26, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Alan M. Krensky, Carol Clayberger
-
Publication number: 20120195854Abstract: Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a tumor antigen or an autoimmune antigen. In another embodiment, the method includes contacting the monocyte with an additional agent that enhances maturation of dendritic cells or induces immunological tolerance. The methods are of use in vivo, in vitro and ex vivo. In another aspect, the disclosure relates to compositions and methods for the treatment of tumors.Type: ApplicationFiled: October 8, 2010Publication date: August 2, 2012Inventors: Alan M. Krensky, Carol Clayberger
-
Patent number: 7745390Abstract: Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.Type: GrantFiled: May 22, 2006Date of Patent: June 29, 2010Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Carol Clayberger, Alan M. Krensky
-
Patent number: 7011834Abstract: Peptide-like compounds and their variants having immunomodulating activity including the N-terminal acylated and/or C-terminal amidated or esterified forms thereof of up to 60 amino acids wherein the peptide-type compound comprises the formula: ??? wherein: ? and ? are the same or different and are of the formula: {R aa76-77 L}(aa79-84)(SEQ ID NO:1) ??(a) or (aa84-79){L aa77-76 R}(SEQ ID NO:2) ??(b) wherein: aa76 is E or V; aa77 is D, S or N; aa79 is R or G; aa80 is I or N; aa81 is a hydrophobic or small amino acid; aa82 is R or L; aa83 is G or R; aa84 is a hydrophobic or small amino acid; wherein the sequence in the brackets may optionally be absent or truncated at any peptide type bond within the brackets may be used by themselves or in combination with immunosuppressant drugs, to reduce CTL activation, particularly in association with transplantation.Type: GrantFiled: May 24, 1996Date of Patent: March 14, 2006Assignee: The Board of Trustees of Leland Stanford Junior UniversityInventors: Carol Clayberger, Alan M. Krensky, Roland Buelow
-
Patent number: 6485928Abstract: The T cell activation marker, granulysin, is demonstrated to be an effective antimicrobial agent. It is used in vitro and in vivo to reduce the population of viable cells in a microbial population. Of particular interest is the use of the active fragment of human granulysin, or modified forms thereof, to treat bacterial infections.Type: GrantFiled: November 3, 1998Date of Patent: November 26, 2002Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of CaliforniaInventors: Steffen Stenger, Robert L. Modlin, Dennis Alan Hanson, Alan M. Krensky
-
Patent number: 6448039Abstract: The present invention provides elements derived from a human RANTES promoter that induce expression of a heterologous coding sequence. The invention further provides expression vectors comprising the elements, and host cells comprising the expression vectors. The invention further provides methods of inducing the expression of a heterologous protein in a host.Type: GrantFiled: June 30, 1999Date of Patent: September 10, 2002Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Peter J. Nelson, Alan M. Krensky, Benjamin D. Ortiz
-
Patent number: 6436903Abstract: Compounds having immunomodulatory activity which are peptide-type compounds, or variants or fragments thereof, including the N-terminal acylated and C-terminal amidated or esterified forms of up to 30 amino acids wherein the peptide-type compound comprises the formula: (a) R aa76-77 L aa79-84 or (b) aa84-79 L aa77-76 R wherein: aa76 is E or V; aa77 is D, S or N; aa79 is R or G; aa80 is I or N; aa81 is a small or hydrophobic amino acid aa82 is R or L; aa83 is G or R; aa84 is a small or hydrophobic amino acid; wherein, in said compounds, at least one of the amino acids is the D isomer are used by themselves or in combination with immunosuppressant drugs, to reduce CTL activation, particularly in association with transplantation.Type: GrantFiled: May 22, 1996Date of Patent: August 20, 2002Assignee: Stanford University (Board of Trustees of the Leland Standford Junior University)Inventors: Carol A. Clayberger, Alan M. Krensky
-
Patent number: 6376240Abstract: A novel zinc finger transcription factore (RFLAT-1) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including diagnostic and therapeutic agent screening applications, as well as in treatment therapies. Also provided are methods of treating disease conditions associated with RANTES function, e.g. inflammation, and the like.Type: GrantFiled: January 27, 2000Date of Patent: April 23, 2002Assignee: Board of Trustees of the Leland Stanford Junior UnversityInventors: An M. Song, Ya-Fen Chen, Alan M. Krensky
-
Publication number: 20020044927Abstract: The T cell activation marker, granulysin, is demonstrated to be an effective antimicrobial agent. It is used in vitro and in vivo to reduce the population of viable cells in a microbial population. Of particular interest is the use of the active fragment of human granulysin, or modified forms thereof, to treat bacterial infections.Type: ApplicationFiled: November 3, 1998Publication date: April 18, 2002Applicant: BOZICEVIC, FIELD AND FRANCIS LLPInventors: STEFFEN STENGER, ROBERT L. MODLIN, DENNIS ALAN HANSON, ALAN M. KRENSKY
-
Patent number: 5935797Abstract: Present invention based on the identification of the molecular interaction that forms the basis of the immunosuppressive activity of peptides comprising residues 71-80 of an MHC Class II protein (Class II peptides). Specifically the present invention discloses that Class II peptides bind to members of the PCNA family of proteins. Based on this observation, present invention provides methods for identifying agents that can be used to modulate immune system activity.Type: GrantFiled: March 28, 1997Date of Patent: August 10, 1999Assignee: Stanford UniversityInventors: Carol Clayberger, Alan M. Krensky
-
Patent number: 5888512Abstract: Fragments from the polymorphic domains of Class I HLA antigen domains are used to modulate T-cell activity. The peptides are from the .alpha.1- or .alpha.2 domains, particularly of the HLA-A, and B antigens. The peptides may be conjugated to other compounds to be used in diagnosis and therapy. The peptides may block lysis, CTL proliferation or have other regulating effects.Type: GrantFiled: March 2, 1992Date of Patent: March 30, 1999Assignee: Board of Trustees of the Leland Stanford Junior UniversityInventors: Carol A. Clayberger, Alan M Krensky
-
Patent number: 5723128Abstract: Fragments from the polymorphic domains of Class I HLA antigen domains are used to modulate T-cell activity. The peptides are from the .alpha.1- or .alpha.2 domains, particularly of the HLA-A, and B antigens. The peptides may be conjugated to other compounds to be used in diagnosis and therapy. The peptides may block lysis, CTL proliferation or have other regulating effects.Type: GrantFiled: April 5, 1994Date of Patent: March 3, 1998Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Carol Clayberger, Alan M. Krensky, Peter Parham
-
Patent number: 5620956Abstract: The present invention provides compositions comprising a peptide having between about 7 and about 20 amino acid residues, the peptide being capable of binding a CD8 molecule on a cytolytic T lymphocyte (CTL) precursor and inhibiting differentiation of the CTL precursor to a mature CTL. The peptides have amino acid sequences substantially homologous to a sequence in an .alpha.3 domain of a human Class I MHC molecule. The sequence from the .alpha.3 domain is preferably between residue 220 and residue 235. The peptides typically comprise the sequences DQTQDTE (SEQ. ID No. 1) or EDQTQDTELVETRP (SEQ. ID No. 2).Type: GrantFiled: July 22, 1994Date of Patent: April 15, 1997Assignee: The Board of Regents of the Leland Stanford Junior UniversityInventors: Carol Clayberger, Alan M. Krensky
-
Patent number: 4994369Abstract: Nucleic acids and peptides are provided which can be used for detecting the status of functional T-lymphocytes as to stimulation and the time of stimulation. The nucleic acids and peptides may be provided by cloning and expression using recombinant techniques. These diagnoses may be used to determine whether T-cells are functional and the degree to which a T-cell population has been stimulated.Type: GrantFiled: December 15, 1987Date of Patent: February 19, 1991Assignee: The Board of Trustees of the Leland Stanford Jr. Univ.Inventors: Alan M. Krensky, Mark Davis, Thomas Schall, Jan Jongstra